ICON has expanded its bioanalytical facilities in the US and the UK, creating space for dedicated immunoassay laboratories to address growing demand for biomarker and cell-based assay services.

The Dublin, Ireland-based provider of global outsourced development services has added 7,000 sq ft and 4,000 sq ft respectively to its bioanalytical laboratories in Whitesboro, New York and Manchester, UK.  Each facility will now house dedicated units for biomarker testing and cell-based assays.

In operation since 1988, the Whitesboro facility already incorporates multiple wet laboratories as well as instrument laboratories for small and large molecules, including a specially designed hazardous lab for analysing HIV & Hepatitis B infected samples.

ICON’s Manchester laboratory, which is situated close to the company’s hospital-based Clinical Pharmacology Unit, has been providing bioanalytical support for both small- and large-molecule studies for nearly 30 years now.

Necessary scale

“We have expanded our bioanalytical facilities to provide the necessary scale to support the ever-broadening range of testing services required by our sponsors,” commented Brian O’Dwyer, senior vice president of global bioanalytical services for ICON Development Solutions.